High Great Innovation has unveiled three cutting-edge drone platforms—EMO Mini, EMO Plus, and FYLO Mini—aimed at transforming both large-scale outdoor formations and intimate indoor displays. By expanding its portfolio, the company promises to deliver safe, stunning aerial performances for a wide range of creative shows.

Arcutis Biotherapeutics, Inc. has approved 61,000 restricted stock units to welcome nine new employees under its 2022 Inducement Plan. This move underscores the company’s dedication to attracting and retaining top professionals in the competitive field of immuno-dermatology.

Anaveon announced the appointment of Laetitia Pouzol as its new Chief Scientific Officer, underscoring the company’s focus on immunology. The press release, originating from the United States, signals a strategic leadership shift at the biotechnology firm.

Biogen will present new findings at the Alzheimer’s Association International Conference (AAIC) 2026, set for July 12–15 in London. This includes data from the Phase 2 CELIA study of diranersen, an investigational tau-targeting ASO, as well as additional analyses of LEQEMBI (lecanemab).

A Pittsburgh-based humanoid robot developer is preparing a move to Wall Street, underscoring the city’s continued ascent as a tech hub. Though details are limited, the announcement suggests a significant milestone for the robotics industry.

A biotech startup focused on eye diseases has secured $330 million in funding, gearing up for late-stage testing of its treatments. This significant investment marks a pivotal moment in ophthalmology care and underlines the growing interest in targeted therapies for chronic conditions.

At Automate 2026, the Nasdaq-listed AIxCrypto introduced RoboShare, a platform that matches robot rentals to potential users, and unveiled AIXC01, a new infrastructure network for autonomous assets. This bold move aims to extend the productive life of robots while connecting them to the latest EAI + Web3 technologies.

Neko Health has introduced new innovations in its Health Scan experience, featuring body composition tracking and deeper integration with wearable devices. These advancements underscore the company’s commitment to continuous innovation and its global vision for proactive healthcare.

Green Bay has officially launched the Drone as First Responder program, a pioneering initiative by the city’s police and fire departments. The program aims to put eyes on the scene faster, thus enhancing situational awareness and response efficiency across all emergency calls.

A new Phase 2 clinical trial is shining a spotlight on the potential benefits of Zabopegdutide for MASH patients. HistoIndex’s AI-powered analysis has revealed robust improvements in liver fibrosis, offering a promising glimpse of future treatment possibilities.

Savara Inc. (Nasdaq: SVRA) is restructuring its executive leadership following the resignation of Chief Financial and Administrative Officer Dave Lowrance for health-related reasons. The move comes as the company anticipates a key drug milestone that could significantly impact its future.

E-Scopics has secured FDA 510(k) clearance for its new Hepatoscope-Derived Fat Fraction (HDFF) technology, combining ultrasound attenuation with backscattering coefficient to measure liver fat. With a documented high correlation to MRI-PDFF, this innovation promises broader access to non-invasive fatty liver assessment.

Uber intends to expand its autonomous offerings by launching a premium robotaxi service in Houston by mid-2027. This second U.S. market under a partnership with electric vehicle maker Lucid and autonomous vehicle startup Nuro follows active preparations in the San Francisco Bay Area.

Syremis Therapeutics, a clinical-stage biopharmaceutical firm, has named Aaron Koenig, MD, as Chief Medical Officer. The appointment underscores the company’s mission to develop novel, impactful medicines for mental health disorders.

Teknova, a leading supplier of critical reagents, has strengthened its existing partnership with Bioz by expanding a customized digital platform. This integration promises to enhance Teknova’s presence in scientific publications and streamline the discovery of new treatments.

Dr. Michael Merzenich’s groundbreaking revelation of adult brain plasticity helped him design the cochlear implant, a device that has restored hearing for more than a million people with deafness. Honored with the Richard N. Merkin Prize in Biomedical Technology, his work continues to reshape global perceptions of what the human brain can achieve.

Inventiva has made its preparatory documents available for a crucial Combined General Meeting on June 30, 2026. This announcement reflects the company’s commitment to providing timely updates on its clinical-stage biopharmaceutical work focusing on MASH therapy.

Oculis Holding AG has embarked on a pioneering effort to tackle dry eye disease using a genotype-based approach. The first patient has been enrolled in the PREDICT-1 registrational trial for Licaminlimab, opening a new chapter in personalized eye care.

China’s top health authority has granted Adcentrx Therapeutics approval to proceed with trials for ADRX-0405, an investigational STEAP1 antibody-drug conjugate aiming to treat late-stage solid tumors, including prostate cancer. Building on progress from its U.S. Phase 1a/1b study, the company aims to broaden the trial’s reach and accelerate patient enrollment by including clinical centers in China.

A sudden 49% plunge in GeneDx Holdings Corp.’s stock value has sparked a securities class action lawsuit. Once touted for its acquisition-driven growth, the company now faces allegations that its financial woes go deeper than a single poor quarter.

Eledon Pharmaceuticals has released updated findings from an investigator-initiated islet transplant trial at UChicago Medicine, focusing on the potential of Tegoprubart in treating Type 1 Diabetes. The new data marks a key step forward for transplant-based research in diabetes care.